RP Bio Inc. (KOSDAQ:314140)
South Korea flag South Korea · Delayed Price · Currency is KRW
5,780.00
+190.00 (3.40%)
At close: Aug 24, 2026

RP Bio Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
6,7264,682-907.125,4374,3163,813
Depreciation & Amortization
6,0796,4126,8186,0485,4035,203
Loss (Gain) From Sale of Assets
284.77178.599.24--150.064.31
Loss (Gain) From Sale of Investments
-35.3-1.59----
Stock-Based Compensation
----5.7710.5414.57
Provision & Write-off of Bad Debts
187.2294.032.70.09-26.95-36.16
Other Operating Activities
4,6123,3931,7942,1067,1493,781
Change in Accounts Receivable
-3,242-1,1352,334777.83-1,651-4,355
Change in Inventory
-3,217-1,26710,2453,755-16,021-6,180
Change in Accounts Payable
784.642,098-3,406-9,0445,2529,117
Change in Other Net Operating Assets
-473.83-2,179-3,3661,505-3,125-1,902
Operating Cash Flow
11,91512,47613,52410,5801,1559,459
Operating Cash Flow Growth
-6.39%-7.75%27.82%816.03%-87.79%46.55%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-3,872-5,200-5,853-11,123-5,147-7,246
Sale of Property, Plant & Equipment
19.5819.5814.3869.73165.55-
Sale (Purchase) of Intangibles
-331.83-411.27-157.78-41.02-132.18-24.59
Investment in Securities
-2,900-1004,405-7,803-7.2308.64
Other Investing Activities
-1,499-1,675390.45-6.67-218.69-204.13
Investing Cash Flow
-7,980-7,066-1,501-18,264-5,939-7,166

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-16,00021,000-14,50023,235
Total Debt Issued
16,00016,00021,000-14,50023,235
Short-Term Debt Repaid
--25,000-21,000-5,000-14,500-26,104
Long-Term Debt Repaid
--688.6-665.09-919.92-453-522.83
Total Debt Repaid
-16,606-25,689-21,665-5,920-14,953-26,627
Net Debt Issued (Repaid)
-606.09-9,689-665.09-5,920-453-3,392
Issuance of Common Stock
----16,287-
Dividends Paid
-432.49--432.49---
Other Financing Activities
500---3.79-502.46-
Financing Cash Flow
-538.58-9,689-1,098-5,92415,332-3,392

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-6.61-6.61----
Miscellaneous Cash Flow Adjustments
-0--0---0
Net Cash Flow
3,390-4,28510,925-13,60810,547-1,099

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
8,0437,2767,670-543.31-3,9922,213
Free Cash Flow Growth
10.90%-5.14%----
Free Cash Flow Margin
5.69%5.34%6.19%-0.36%-2.89%1.93%
Free Cash Flow Per Share
929.49841.15887.85-58.16-560.54336.69
Levered Free Cash Flow
6,3575,3026,556-6,112-3,592-1,246
Unlevered Free Cash Flow
6,7325,8207,338-4,990-2,852-633.95

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
596.94831.791,3161,816989.75638.38
Cash Income Tax Paid
595.36394.19439.62992.04246.9122.34
Change in Working Capital
-6,148-2,4825,807-3,006-15,546-3,321